A multi-centre, randomised, double-blind, placebo-controlled escalating dose ranging phase II study on the efficacy of DEBIO-025 to reduce HCV viral load in combination with PEGASYS 180 g/week in treatment na ve patients with chronic hepatitis C and on the safety of this combination therapy

Trial Profile

A multi-centre, randomised, double-blind, placebo-controlled escalating dose ranging phase II study on the efficacy of DEBIO-025 to reduce HCV viral load in combination with PEGASYS 180 g/week in treatment na ve patients with chronic hepatitis C and on the safety of this combination therapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Alisporivir; Peginterferon alfa-2a
  • Indications Hepatitis C
  • Focus Pharmacodynamics; Therapeutic Use
  • Sponsors Debiopharm
  • Most Recent Events

    • 26 Apr 2009 Pharmacodynamic results reported at the 44th Annual Meeting of the European Association for the Study of the Liver.
    • 28 Apr 2008 Interim results have been presented at EASL according to a Debiopharm media release.
    • 24 Apr 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top